Abstract
Thrombocytopenia is common in advanced liver disease, and such patients frequently need invasive procedures. Numerous mechanisms for thrombocytopenia exist, including splenic sequestration and reduction of levels of the platelet growth factor thrombopoietin. Traditionally, platelet transfusions have been used to increase platelet counts before elective procedures, usually to a threshold of greater than or equal to 50,000/μL, but levels vary by provider, procedure, and specific patient. Recently, the thrombopoietin receptor agonists avatrombopag and lusutrombopag were studied and found efficacious for increasing platelet count in the outpatient setting for select patients with advanced liver disease who need a procedure.
Original language | English (US) |
---|---|
Pages (from-to) | 437-451 |
Number of pages | 15 |
Journal | Clinics in liver disease |
Volume | 24 |
Issue number | 3 |
DOIs | |
State | Published - Aug 2020 |
Funding
K.M. Nilles has nothing to disclose. S.L. Flamm is a consultant for Shionogi.
Keywords
- Advanced liver disease
- Cirrhosis
- Invasive procedures
- Low platelets
- TPO receptor agonists
- Thrombocytopenia
- Thrombopoietin
ASJC Scopus subject areas
- Hepatology